Johnson & Johnson (JNJ), Dendreon Corporation (DNDN): A Magical Drug that Could Change Lives

Page 1 of 2

The biotech sector is perhaps the most volatile and risk-prone sector in the market, but investors still love it. Medical science is leaping forward and new drugs keep hitting the Street, but the hunt for the “safer and more effective drug” is always on. It’s for this reason that we often see contrarians being rewarded massively for their daring positions. The company in focus is Dendreon Corporation (NASDAQ:DNDN), and here are a few reasons why I think it could prove to be a great investment.

Johnson & Johnson (JNJ)

The magic drug

To begin with, Dendreon has absolutely ridiculous fundamentals. From towering debt/equity to plummeting profitability, it gets filtered out as a poor stock. But history doesn’t ascertain the future, right?

Dendreon Corporation (NASDAQ:DNDN) was able to develop an immunotherapy treatment called Provenge that attacks cancer cells by boosting a person’s immunity. This not only contributes to cancer reduction/remission, but also improves a person’s defense system against common illnesses like the flu or infections. Unlike chemotherapy and other radiation treatments, this is a more natural approach, but also has its share of side effects. Its common side effects include chills and fatigue, but it’s still way better than chemotherapy, which causes hair loss, bleeding, and body aches. Provenge competes with Xtandi, developed by Medivation Inc. (NASDAQ:MDVN), and Zytiga, developed by Johnson & Johnson (NYSE:JNJ).

Studies have shown that prostrate specific serum antigen levels shrank by up to 85% when Xtandi was used for a month. Zytiga springs into action soon after it has been prescribed, but Provenge takes at least 2-3 months to even show signs of recovery. But, the good thing is that Provenge uses immunotherapy, which is considered to have fewer side effects than its peers.

This is indeed a revolutionary breakthrough, and just like any new business model, it, too, had a painfully long fertility period. Shares of Dendreon were continuously hammered as the company reported a streak of lower-than-expected sales of its cancer treatment procedure, Provenge. This, coupled with poor margins, brought financial havoc upon the company. For the recent quarter, the company reported a net loss of $0.26 per share, compared to a profit of $0.26 per share in Q4 2011. Its quarterly revenue also plunged to $85 million, down from $202 million in Q4 2011.

But, the Street was absolutely delighted, as it was expecting a loss of $0.55 per share. Moreover, the company reported annual sales to the tune of $325.3 million, up from $213.5 million in FY11. Its streak of poor sales finally seems to be over. Its peers are also performing well. Medivation’s Xtandi was launched in Sept. 2012. Its first full quarter sales stood at a solid $57 million and the management expects its Xtandi sales to cross $100 million, and even beat the street’s estimates. Johnson & Johnson (NYSE:JNJ) also recorded impressive sales growth of 6.8% for Zytiga, but its relatively weaker FY13 guidance disappointed the street. For FY13, Johnson & Johnson is expecting to earn $5.35-$5.45 per share.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!